• Seeking Alpha

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

Seeking Alpha / 6 minutes from now 2 Views

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity

Read more
  • Source:
  • GlobeNewswire - News about Public Companies
Previous post
illumin Reports Third Quarter 2025 Financial Results
Next post
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Comments

Just Posted

  • SalMar - Release of employee restricted share units in SalMar ASA ("the Company")

    4 hours from now

  • SalMar - Frigivelse av ansattes Restricted Share Units i SalMar ASA ("Selskapet")

    4 hours from now

  • VALLOUREC ANNOUNCES A TRANSITION IN ITS FINANCIAL MANAGEMENT

    4 hours from now

  • VALLOUREC ANNONCE UNE TRANSITION À LA DIRECTION FINANCIERE

    4 hours from now

  • Fagron’s share buy-back program: Weekly update

    4 hours from now

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Reviews

Categories

  • Seeking Alpha 1767

Categories

  • Seeking Alpha 1767

Pages

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Copyright News That Move � 2018. All Rights Reserved

  • Seeking Alpha
  • Trade Halts